세계의 항감염증약 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)
Global Anti-Infective Agents Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
상품코드:1521400
리서치사:Value Market Research
발행일:2024년 07월
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
항감염증약 시장의 세계 수요는 2023년 1,747억 달러에서 2032년에는 2,038억 6,000만 달러 가까운 시장 규모에 달할 것으로 추정되며, 조사 기간인 2024-2032년 CAGR은 1.73%입니다.
항감염증약은 바이러스, 세균, 곰팡이, 기생충 등 다양한 병원균에 의한 감염증을 예방하고 치료하기 위해 사용되는 의약품입니다. 항생제, 항바이러스제, 항진균제, 항기생충제 등이 포함됩니다. 이들 약제는 감염성 생물의 증식을 억제하거나 사멸시킴으로써 효과를 발휘합니다. 항감염증약의 선택은 감염증의 유형, 원인 병원체, 환자의 건강 상태에 따라 달라집니다. 이러한 약물의 적절한 사용은 내성균의 발생을 방지하고 감염증의 효과적인 치료를 보장하며 공중 보건을 보호하는 데 필수적입니다.
시장 역학
박테리아, 바이러스, 곰팡이, 기생충 감염증의 발병률이 증가함에 따라 효과적인 항감염증 약물의 개발 및 보급이 요구되고 있습니다. 의학 연구의 발전으로 새로운 항생제, 항바이러스제, 항진균제, 항기생충제 등이 개발되어 내성균주에 대한 대응과 치료 성적을 향상시키고 있습니다. 또한 조기 및 적절한 감염 치료의 중요성에 대한 인식이 높아지면서 수요를 촉진하고 있습니다. 또한 개발도상국의 의료 인프라 확충과 의료 서비스 접근성 향상도 중요한 역할을 하고 있습니다. 정부의 지원책과 감염성 질환 연구에 대한 자금 지원도 시장을 더욱 자극하고 있습니다. 병원내 감염이 증가함에 따라 효과적인 항감염증약의 필요성이 증가하고 있습니다. 제약사들의 연구개발 투자, 전략적 제휴, 의약품 개발을 위한 공동연구는 새로운 첨단 항감염증약 도입을 가속화하고 시장 성장을 가속하고 있습니다. 그러나 내성균의 출현과 치료로 인한 부작용은 향후 수년간 시장 성장에 도전이 될 수 있습니다.
조사 리포트는 Porter's Five Forces 모델, 시장의 매력 분석, 밸류체인 분석을 다루고 있습니다. 이러한 툴은 업계의 구조를 명확하게 파악하고, 세계 레벨에서의 경쟁 매력을 평가하는데 도움이 됩니다. 또한 이러한 툴은 세계의 항감염증약 시장의 각 부문을 종합적으로 평가할 수도 있습니다. 항감염증약 업계의 성장과 동향은 이 조사에 전체적인 어프로치를 제공합니다.
시장 세분화
항감염증약 시장 보고서의 이 섹션에서는 국가 및 지역 레벨 부문에 관한 상세 데이터를 제공하며, 이에 따라 전략가가 향후 비지니스 기회와 함께 각각의 제품 및 서비스의 타깃층을 식별하는데 도움이 됩니다.
The global demand for Anti-Infective Agents Market is presumed to reach the market size of nearly USD 203.86 Billion by 2032 from USD 174.7 Billion in 2023 with a CAGR of 1.73% under the study period 2024-2032.
Anti-infective agents are medications used to prevent and treat infections caused by various pathogens, including viruses, bacteria, fungi, and parasites. They include antibiotics, antivirals, antifungals, and antiparasitic drugs. These agents work by inhibiting the growth of or killing infectious organisms. The choice of anti-infective agent depends on the type of infection, the causative pathogen, and the patient's health condition. Proper use of these agents is essential to prevent the development of resistance, ensure effective treatment of infections, and safeguard public health.
MARKET DYNAMICS
The rising incidence of bacterial, viral, fungal, and parasitic infections necessitates the development and availability of effective anti-infective agents. Advances in medical research have led to the creation of novel antibiotics, antivirals, antifungals, and antiparasitics, addressing resistant strains and improving treatment outcomes. The growing awareness of the importance of early and appropriate infection treatment also boosts demand. Additionally, expanding healthcare infrastructure in developing regions and increasing accessibility to healthcare services play crucial roles. Supportive government initiatives and funding for infectious disease research further stimulate the market. The increasing occurrence of hospital-acquired infections underscores the need for effective anti-infective agents. Pharmaceutical companies' investment in R&D, strategic partnerships, and collaborations for drug development accelerate the introduction of new and advanced anti-infective agents, driving market growth. However, the emergence of resistant strains and side effects of treatments may challenge market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anti-Infective Agents. The growth and trends of Anti-Infective Agents industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Anti-Infective Agents market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Anti-Infective Agents market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anti-Infective Agents market include Pfizer Inc., Abbott, Gilead Sciences Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Sandoz International GmbH, B. Braun SE, Xellia Pharmaceuticals, Mankind Pharma, Bayer AG, AstraZeneca, Boehringer Ingelheim International GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.1 Market Attractiveness Analysis By Type/Drug Class
3.7.2 Market Attractiveness Analysis By Route of Administration
3.7.3 Market Attractiveness Analysis By Distribution Channel
3.7.4 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY TYPE/DRUG CLASS
5.1. Overview By Type/Drug Class
5.2. Historical and Forecast Data Analysis By Type/Drug Class
5.3. Antibacterials (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others) Historic and Forecast Sales By Regions
5.4. Antivirals Historic and Forecast Sales By Regions
5.5. Antifungals (Azoles, Echinocandins, Polyenes, Others) Historic and Forecast Sales By Regions
6. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Topical Historic and Forecast Sales By Regions
6.4. Oral Historic and Forecast Sales By Regions
6.5. IV Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions
7. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
7.4. Retail Pharmacies Historic and Forecast Sales By Regions
7.5. Specialty Pharmacies Historic and Forecast Sales By Regions
7.6. E-Commerce Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions
8. GLOBAL ANTI-INFECTIVE AGENTS MARKET ANALYSIS BY GEOGRAPHY
8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
8.3.1 Overview, Historic and Forecast Data Sales Analysis
8.3.2 North America By Segment Sales Analysis
8.3.3 North America By Country Sales Analysis
8.3.4 United States Sales Analysis
8.3.5 Canada Sales Analysis
8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
8.4.1 Overview, Historic and Forecast Data Sales Analysis
8.4.2 Europe By Segment Sales Analysis
8.4.3 Europe By Country Sales Analysis
8.4.4 United Kingdom Sales Analysis
8.4.5 France Sales Analysis
8.4.6 Germany Sales Analysis
8.4.7 Italy Sales Analysis
8.4.8 Russia Sales Analysis
8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
8.5.1 Overview, Historic and Forecast Data Sales Analysis
8.5.2 Asia Pacific By Segment Sales Analysis
8.5.3 Asia Pacific By Country Sales Analysis
8.5.4 China Sales Analysis
8.5.5 India Sales Analysis
8.5.6 Japan Sales Analysis
8.5.7 South Korea Sales Analysis
8.5.8 Australia Sales Analysis
8.5.9 South East Asia Sales Analysis
8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
8.6.1 Overview, Historic and Forecast Data Sales Analysis
8.6.2 Latin America By Segment Sales Analysis
8.6.3 Latin America By Country Sales Analysis
8.6.4 Brazil Sales Analysis
8.6.5 Argentina Sales Analysis
8.6.6 Peru Sales Analysis
8.6.7 Chile Sales Analysis
8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
8.7.1 Overview, Historic and Forecast Data Sales Analysis
8.7.2 Middle East & Africa By Segment Sales Analysis
8.7.3 Middle East & Africa By Country Sales Analysis
8.7.4 Saudi Arabia Sales Analysis
8.7.5 UAE Sales Analysis
8.7.6 Israel Sales Analysis
8.7.7 South Africa Sales Analysis
8.7.8 Rest Of Middle East And Africa Sales Analysis
9. COMPETITIVE LANDSCAPE OF THE ANTI-INFECTIVE AGENTS COMPANIES
9.1. Anti-Infective Agents Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments
10. COMPANY PROFILES OF ANTI-INFECTIVE AGENTS INDUSTRY
10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
10.3.1 Company Overview
10.3.2 Company Revenue
10.3.3 Products
10.3.4 Recent Developments
10.4. Abbott
10.4.1 Company Overview
10.4.2 Company Revenue
10.4.3 Products
10.4.4 Recent Developments
10.5. Gilead Sciences Inc.
10.5.1 Company Overview
10.5.2 Company Revenue
10.5.3 Products
10.5.4 Recent Developments
10.6. Bristol-Myers Squibb Company
10.6.1 Company Overview
10.6.2 Company Revenue
10.6.3 Products
10.6.4 Recent Developments
10.7. Merck & Co. Inc.
10.7.1 Company Overview
10.7.2 Company Revenue
10.7.3 Products
10.7.4 Recent Developments
10.8. Sandoz International GmbH
10.8.1 Company Overview
10.8.2 Company Revenue
10.8.3 Products
10.8.4 Recent Developments
10.9. B. Braun SE
10.9.1 Company Overview
10.9.2 Company Revenue
10.9.3 Products
10.9.4 Recent Developments
10.10. Xellia Pharmaceuticals
10.10.1 Company Overview
10.10.2 Company Revenue
10.10.3 Products
10.10.4 Recent Developments
10.11. Mankind Pharma
10.11.1 Company Overview
10.11.2 Company Revenue
10.11.3 Products
10.11.4 Recent Developments
10.12. Bayer AG
10.12.1 Company Overview
10.12.2 Company Revenue
10.12.3 Products
10.12.4 Recent Developments
10.13. AstraZeneca
10.13.1 Company Overview
10.13.2 Company Revenue
10.13.3 Products
10.13.4 Recent Developments
10.14. Boehringer Ingelheim International GmbH
10.14.1 Company Overview
10.14.2 Company Revenue
10.14.3 Products
10.14.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies
